Vitamin D status and colorectal neoplasm risk in Lynch syndrome
Abstract Background: Higher circulating vitamin D concentrations have been associated with a decreased colorectal neoplasm (CRN) risk in the general population. However, this association has not yet been investigated in individuals with Lynch syndrome (LS), an inherited predisposition to colorectal cancer. Methods: The study population included 2,351 LS carriers from the GEOLynch and the Colon Cancer Family Registry cohorts. Total plasma 25-hydroxyvitamin D (25(OH)D2 and 25(OH)D3) concentrations were measured using isotope-dilution Liquid Chromatography–tandem Mass Spectrometry. CRNs included adenoma, serrated lesions, and colorectal cancer. Multivariable Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between 25-hydroxyvitamin D concentrations and CRN risk, overall and by pathogenic variant type, age, sex, CRN history and geographic region. Results: During a median follow-up of 7.2 years [IQR: 3.3-12.6], 647 (27.5%) LS carriers developed a CRN. No association was observed for deficient (<50 nmol/L or <20 ng/mL; HR: 1.12; 95% CI: 0.91, 1.39) or optimal (≥75 nmol/L or ≥30 ng/mL; HR: 0.94; 95% CI: 0.77, 1.15) compared with sufficient (50–<75 nmol/L or 20-<30 ng/mL) vitamin D concentrations. No association was observed for each 10 nmol/L or 4 ng/mL increment in vitamin D concentration. Among PMS2 carriers, a 10 nmol/L increment was associated with a 27% lower CRN risk (HR: 0.73; 95% CI: 0.58-0.91). Conclusions: Vitamin D concentrations were not associated with CRN risk among LS carriers, whereas the association observed among PMS2 carriers warrants further investigation. Impact: If confirmed, these findings could inform personalized risk reduction strategies for PMS2 carriers.
Authors
- Ellen Kampman (ORCID: https://orcid.org/0000-0002-8606-7075)
- Laura N. Anderson (ORCID: https://orcid.org/0000-0002-6106-5073)
- Tanya M. Bisseling (ORCID: https://orcid.org/0000-0001-7976-7949)
- Polly A. Newcomb (ORCID: https://orcid.org/0000-0001-8786-0043)
- Loı̈c Le Marchand (ORCID: https://orcid.org/0000-0001-5013-980X)
- Jan Jacob Koornstra (ORCID: https://orcid.org/0000-0001-8400-2131)
- Fränzel J.B. van Duijnhoven (ORCID: https://orcid.org/0000-0001-8367-2352)
- Monique Esther van Leerdam (ORCID: https://orcid.org/0000-0002-5719-3208)
- Evertine Wesselink (ORCID: https://orcid.org/0000-0001-9347-7913)
- Michelle Cotterchio (ORCID: https://orcid.org/0000-0003-2862-7895)
- Stephanie L. Schmit (ORCID: https://orcid.org/0000-0001-5931-1194)
- Jody M.W. van den Ouweland (ORCID: https://orcid.org/0000-0003-0605-7756)
- Niloy Jewel Samadder (ORCID: https://orcid.org/0009-0003-9740-9696)
- Femke Fleur Verstraete (ORCID: https://orcid.org/0009-0000-8381-6467)
- Marjolein T. Bulbaai (ORCID: https://orcid.org/0009-0000-9466-5940)
Institutions
- Cleveland Clinic (US)
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- University of Toronto (CA)
- Dutch Cancer Society (NL)
- Radboud University Medical Center (NL)
- Fred Hutch Cancer Center (US)
- Cancer Center of Hawaii (US)
- Oncode Institute (NL)
- Canisius-Wilhelmina Ziekenhuis (NL)
- Mayo Clinic Hospital (US)
- Wageningen University & Research (NL)
- McMaster University (CA)
Publication Details
- Journal
- Cancer Epidemiology Biomarkers & Prevention
- Published
- 2026-09-30
- DOI
- https://doi.org/10.1158/1055-9965.epi-26-0722
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00